Introduction
============

Postmastectomy radiotherapy (PMRT), as a treatment modality for postoperative patients with breast cancer, is primarily used to reduce locoregional recurrence (LRR) and improve survival, although modestly, in patients with high-risk factors[@r1]^-^[@r4].

According to the National Comprehensive Cancer Network (NCCN) guidelines[@r5], PMRT should be considered for patients with T~3~-T~4~ breast cancer with more than three positive lymph nodes or with T~1~-T~2~ breast cancer with one to three positive lymph nodes. Given that several clinical and pathological factors may affect prognosis of patients with intermediate-risk breast cancer, using T/N classification only is an imprecise method in determining whether a patient should be considered for PMRT[@r6]^-^[@r9]. Several researchers have attempted to identify the risk factors for LRR and mortality after mastectomy to select patients who are most likely to benefit from PMRT[@r1]^-^[@r4]^,^[@r6]^-^[@r18]. However, these patient subgroups have not been clearly defined, and the contribution of PMRT to locoregional control and survival remains unclear.

The function of PMRT is not clearly defined in breast cancer patients with one to three positive lymph nodes. In this retrospective study, we identified prognostic factors for LRR and mortality of T~1~-T~2~ N~1~ and T~3~-T~4~ N~1~ breast cancer patients. In addition, we compared the locoregional failure-free survival (LRFFS) and overall survival (OS) of the high-risk patients with and without PMRT to define a subgroup of patients who might benefit from PMRT.

Materials and methods
=====================

Clinical data
-------------

From January 2000 to December 2002, breast cancer patients with pathologically proven one to three positive axillary lymph nodes (ALNs) were treated with modified radical mastectomy plus axillary dissection at the Tianjin Cancer Hospital. Of the 527 patients with one to three positive lymph nodes, the median age was 48.73 years (range, 26 to 79 years). The median number of involved ALNs was 1.93 (range, 1 to 3). A total of 432 patients with T~1~-T~2~ disease and 95 patients with T~3~-T~4~ disease were included in the study, 75.7% (327/432) and 70.5% (67/95) of whom received PMRT, respectively. The study was approved by the institutional ethics committee.

Systemic treatment
------------------

All patients received TEC-based (docetaxel, epirubicin, cyclophosphamide) or docetaxel-containing regimens as adjuvant chemotherapy. Adjuvant endocrine therapy was performed for 5 years in all patients who had positive hormone receptors. Among 527 patients, 74.8% (394/527) underwent PMRT, which was delivered to the breast, chest wall, internal mammary, supraclavicular, and axillary fossa drawing region by medial and lateral-tangential fields with external-beam irradiation (4 or 6 MV photons/60 Co). The standard dose to the entire chest wall was 50 Gy (range, 46 to 54 Gy), 1.8 to 2 Gy/d, and five times weekly. The supraclavicular region and the full axilla were treated with a dose of 50 Gy using an anterior field. An additional external boost with electrons (2 Gy/10 Gy to 14 Gy) was performed in patients who had locally advanced disease.

Follow-up
---------

The median time of follow-up was 127.82 months (range, 15 to 155 months). All intervals were calculated from the date of completion of surgery, and the endpoint was defined as the last follow-up or death. Evaluation of tumor control was performed for patients in 4-month intervals for the first 2 years and in 6-month intervals for the next 3 years. Subsequently, these patients were observed on a yearly basis. Clinical examinations, which included blood sampling, routine chest radiograph, mammograph, and ultrasound, were performed as evaluation during the follow-up. Further evaluations were conducted only if the clinical findings indicated a disease progression. Survival period was calculated from the date of surgical resection to the date of last follow-up. The endpoints of interest included LRFFS and OS.

Recurrence
----------

LRR was identified as local recurrence (chest wall alone) or regional recurrence (axillary, supraclavicular, and internal mammary lymph nodes alone). Any recurrence outside these areas was defined as distant metastasis (DM).

Statistical analysis
--------------------

All analyses were performed using SPSS 19.0. Pearson's χ^2^-test was used to compare the proportions of categorical covariates among the groups of patients with different T stages. OS and LRFFS were analyzed with Kaplan-Meier method. Univariate and multivariate hazard ratios (HR) and their 95% confidence intervals (CIs) were calculated using Cox's proportional hazard model. A probability level of ≤0.05 was considered statistically significant.

Results
=======

Basic information
-----------------

With a median follow up of 127.82 months (range, 15 to 155 months), 3.7% (16/432) and 14.7% (14/95) of patients developed LRR in T~1~-T~2~ N~1~ and T~3~-T~4~ N~1~ patient groups, respectively. OS was 93.5% (404/432) and 45.3% (43/95) in the T~1~-T~2~ N~1~ and T~3~-T~4~ N~1~ groups, respectively. The Kaplan-Meier curves of LRFFS and OS in different T stages confirmed the statistically significant difference in LRFFS and OS between the T~1~-T~2~ N~1~ and T~3~-T~4~ N~1~ patients ([**Figure 1A,B**](#f1){ref-type="fig"}). The distribution patterns of clinico-pathologic characteristics for the PMRT and non-PMRT groups are presented in [**Table 1**](#t1){ref-type="table"}. A statistically significant difference was observed between the two groups regarding the status of extracapsular extension (ECE) and the number of involved ALNs (*P*\<0.05).

![(A) Kaplan-Meier curve of LRFFS in different T stages; (B) Kaplan-Meier curve of OS in different T stages; (C) Kaplan-Meier curve of OS in patients with different ECE in T~1~-T~2~ N~1~ patients. PMRT+E-- *vs*. PMRT--E--: *P*=0.502; PMRT+E+ *vs*. PMRT--E+: *P*=0.007 (PMRT--, non-PMRT; PMRT+, PMRT; E--, ECE--; E+, ECE+); (D) Kaplan-Meier curve of LRFFS in patients with different ECE in T~1~-T~2~ N~1~ patients. PMRT+E-- *vs*. PMRT--E--: *P*=0.987; PMRT+E+ *vs*. PMRT-E+: *P*=0.026; (E) Kaplan-Meier curve of OS in patients with different histological grades in T~1~-T~2~ N~1~ patients. PMRT+ GI-II *vs*. PMRT-- GI-II: *P*=0.296; PMRT-- GIII *vs*. PMRT+ GIII: *P*=0.007. (GI-II, grade I-II; GIII, grade III); (F) Kaplan-Meier curve of LRFFS in patients with different histological grades in T~1~-T~2~ N~1~ patients. PMRT+ GI-II *vs*. PMRT-- GI-II: *P*=0.816; PMRT-- GIII *vs*. PMRT+ GIII: *P*\<0.001; (G) Kaplan-Meier curve of OS in patients with different hormone receptor status in T~3~-T~4~ N~1~ patients. PMRT+ER/PR-- *vs*. PMRT--ER/PR--: *P*=0.039; PMRT+ER/PR+ *vs*. PMRT--ER/PR+: *P*=0.695; (H) Kaplan-Meier curve of LRFFS in patients with different hormone receptor status in T~3~-T~4~ N~1~ patients. PMRT+ER/PR-- *vs*. PMRT--ER/PR--: *P*=0.046; PMRT+ER/PR+ *vs*. PMRT--ER/PR+: *P*\<0.001.](cbm-11-02-123-f1){#f1}

###### Clinicopathologic features of patients in the study

  Characteristics      No. of patients     *P*
  -------------------- ----------------- ---------
  Age, yrs                               0.841
     ≤50               208               72
     \>50              186               61
  ER/PR                                  0.052
     Negative          54                28
     Positive          340               105
  Postmenopausal                         0.133
     No                201               78
     Yes               193               55
  ECE                                    \<0.001
     Negative          324               87
     Positive          70                46
  Histological grade                     0.21
     I-II              364               118
     III               30                15
  T stage                                0.299
     T~1~-T~2~         327               105
     T~3~-T~4~         67                28
  Endocrine therapy                      0.131
     No                57                27
     Yes               337               106
  ALN                                    \<0.001
     1                 158               38
     2                 129               25
     3                 107               70

ER, estrogen receptor; PR, progesterone; ER/PR, estrogen receptor and progesterone receptor; ECE, extracapsular extension; ALN, axillary lymph nodes; PMRT, postmastectomy radiotherapy.

Univariate and multivariate analyses
------------------------------------

The univariate and multivariate factors for LRR in the different T stages were analyzed using Cox's proportional hazard model. The risk and protective factors in T~1~-T~2~ and T~3~-T~4~ patients were different. ECE (HR=2.867; 95% CI: 1.035-7.939; *P*=0.043) and histological grade III (HR=9.219; 95% CI: 2.956-28.747; *P*=0.000) were the risk factors in T~1~-T~2~ patients. For the T~3~-T~4~ patients, the risk factor was estrogen receptor and progesterone receptor (ER/PR) (--) tumors, whereas the protective factors were ER/PR (+) tumors (HR=0.098; 95% CI: 0.025-0.389; *P*=0.001) and PMRT (HR=0.089; 95% CI: 0.210-0.378; *P*=0.001) ([**Tables 2**](#t2){ref-type="table"}**,**[**3**](#t3){ref-type="table"}).

###### Multivariate analysis with Cox proportional hazards model for OS and LRFFS of T~1~-T~2~ N~1~ patients

  Variable             OS                    LRFFS                             
  -------------------- ------- ------------- ------- -- ------- -------------- -------
  Histological grade   3.365   1.332-8.602   0.010      9.219   2.956-28.747   0.000
  ER/PR                1.716   0.679-4.333   0.627      1.375   0.390-4.849    0.362
  PMRT                 0.914   0.478-1.745   0.784      0.726   0.233-2.265    0.582
  ECE                  1.086   1.012-1.164   0.022      2.867   1.035-7.939    0.043

OS, overall survival; LRFFS, locoregional failure-free survival; HR, hazard ratio; CI, confidence interval; ER/PR, estrogen receptor and progesterone receptor; PMRT, postmastectomy radiotherapy; ECE, extracapsular extension.

###### Multivariate analysis with cox proportional hazards model for OS and LRFFS of T~3~-T~4~ N~1~ patients

  Variable             OS                    LRFFS                             
  -------------------- ------- ------------- ------- -- ------- -------------- -------
  Histological grade   1.845   0.957-3.556   0.067      0.337   0.063-1.795    0.202
  ER/PR                0.307   0.154-0.610   0.001      0.098   0.025-0.389    0.001
  PMRT                 1.251   0.597-2.622   0.552      0.089   0.210-0.378    0.001
  ECE                  0.979   0.533-1.801   0.947      2.702   0.633-11.529   0.179

OS, overall survival; LRFFS, locoregional failure-free survival; HR, hazard ratio; CI, confidence interval; PMRT, postmastectomy radiotherapy; ECE, extracapsular extension.

The factors affecting OS varied between the T~1~-T~2~ N~1~ and T~3~-T~4~ N~1~ patients. ECE (HR=1.086; 95% CI: 1.012-1.164; *P*=0.022) and histological grade III (HR=3.365; 95% CI: 1.332-8.602; *P*=0.010) were the risk factors in T~1~-T~2~ patients. However, the risk factor in T~3~-T~4~ patients was ER/PR (--) tumors. ER/PR (+) tumors (HR=0.307; 95% CI: 0.154-0.610; *P*=0.001) had a significant effect in improving OS ([**Tables 2**](#t2){ref-type="table"}**and**[**3**](#t3){ref-type="table"}).

Effects of PMRT on LRFFS and OS of T~1~-T~2~ N~1~ patients based on ECE status and histological grade
-----------------------------------------------------------------------------------------------------

The OS and LRFFS were analyzed by Kaplan-Meier, and survival curves were plotted for the T~1~-T~2~ N~1~ patient subgroups: ECE (--) /PMRT (--), ECE (--) /PMRT (+), ECE (+) /PMRT (--), and ECE (+) /PMRT (+). The log-rank test results showed that PMRT had statistically positive effects on improving LRFFS (*P*=0.026) and OS (*P*=0.007) of T~1~-T~2~ N~1~ patients with ECE (+) but not ECE (--). We also performed a subgroup analysis according to the histological grade, and the results showed that PMRT could improve the LRFFS (*P*\<0.001) and OS (*P*=0.007) of T~1~-T~2~ N~1~ patients with histological grade III ([**Figure 1C-F**](#f1){ref-type="fig"}).

Effects of PMRT on LRFFS and OS of T~3~-T~4~ N~1~ patients based on hormone receptor status
-------------------------------------------------------------------------------------------

With regard to LRFFS and OS of T~3~-T~4~ N~1~ patients, ER/PR (+) was a statistically significant factor on multivariate analysis. PMRT was beneficial on LRFFS of all patients regardless of the hormone receptor status. The effects of PMRT on LRFFS and OS of the patients with different ER/PR statuses were examined. All T~3~-T~4~ N~1~ patients were first stratified into subgroups of ER/PR (+) and ER/PR (--). We observed that PMRT was useful for the reduction of LRR (*P*\<0.001) of T~3~-T~4~ N~1~ patients with ER/PR (+) but failed to improve OS (*P*=0.695). However, patients with ER/PR (--) could benefit from PMRT on improving LRFFS (*P*=0.046) and OS (*P*=0.039) ([**Figure 1G,H**](#f1){ref-type="fig"}).

Discussion
==========

The significance of PMRT to reduce LRR and total mortality in the subgroup of patients with one to three positive lymph nodes remains unclear[@r7]^,^[@r11]^-^[@r16]. Currently, the indication of PMRT is mainly determined by the number of positive lymph nodes and the T stage. However, some studies[@r10]^,^[@r16]^,^[@r19]^,^[@r20] have reported the comparatively more effective prognostic predictors other than T and N stage that guide the PMRT treatment. These predictors include age, hormone receptor status, ECE status, histological grade, lymphovascular invasion, menstrual status, and lymph node ratio.

Huang *et al*.[@r12] highly recommends the PMRT to breast cancer patients with T~1~-T~2~ and one to three positive lymph nodes for reducing LRR and improving disease-free survival. Tendulkar *et al*.[@r16] suggested that PMRT provides excellent locoregional control for patients with one to three positive lymph nodes, regardless of PMRT patients in more advanced stage (about 40% had stage T~3~-T~4~ disease) and a greater number of risk factors, such as pathological grade III and ECE. However, Geng *et al*.[@r17] suggested that PMRT does not significantly improve the LRFFS for patients with one to three positive axillary nodes, regardless of the ECE status. Kong *et al*.[@r18] found that PMRT does not improve LRR, DM-free survival, or OS in T~1~-T~2~ N~1~ breast cancer patients. However, PMRT might be beneficial in a subgroup of patients with histological grade III disease, ECE, or triple-negative subtype. PMRT is important in identifying the risk factors associated with increased risk of LRR and total mortality in patients with one to three positive axillary lymph nodes to establish its indications.

According to the American Society of Clinical Oncology[@r21], insufficient evidence exists to formulate recommendations or suggestions for the routine use of PMRT in patients with T~1~-T~2~ breast cancer and one to three positive lymph nodes. However, PMRT has been considered for T~1~-T~2~ N~1~ patients based on the NCCN guidelines[@r5]. Our retrospective study provided some new information with regard to patients with one to three positive axillary lymph nodes, who may benefit from PMRT.

Based on our study, different effects of PMRT on improving LRFFS or OS were found between the T~1~-T~2~ N~1~ and T~3~-T~4~ N~1~ patients. Previous studies have reported[@r15]^,^[@r16] that the LRFFS and OS of T~1~-T~2~ N~1~ breast cancer patients treated with radical mastectomy are dependent on several prognostic factors other than T and N stage. Our analysis revealed that ECE (+) and histological grade III were the high-risk factors for LRR and mortality of T~1~-T~2~ N~1~ patients. The stratification analysis results revealed that PMRT had a positive effect in reducing ECE (+) or histological grade III-related LRR and mortality. However, the remaining patients with ECE (--) or histological grade I-II experienced extremely low LRR and mortality rates after mastectomy treatment, and the benefit from PMRT was minimal. Although PMRT had no protective function in improving LRFFS and OS of the general T~1~-T~2~ N~1~ patients, high-risk patients with ECE (+) and histological grade III could benefit from PMRT.

Contrary to T~1~-T~2~ N~1~ patients, the general T~3~-T~4~ N~1~ patients could benefit from PMRT in terms of LRFFS but not in OS. Stage T~3~-T~4~ is a high-risk factor in breast cancer patients, who are more likely to develop DM than patients with early T stage disease. Breast cancer tends to be a systemic disease with potential sub-clinical DM in Fisher's theory[@r17]. Our analysis revealed that PMRT could improve the LRR control in T~3~-T~4~ patients, but no statistically significant effect on OS was observed among these patients. In addition, patients with ER/PR (+) benefited from endocrine therapy. All patients with ER/PR (+) who were included in our study received endocrine therapy. Endocrine therapy was a protective factor to improve LRFFS and OS of T~3~-T~4~ N~1~ patients according to the multivariate analysis results. Thus, the risks of LRR and mortality were positively associated with ER/PR (--). NCCN guidelines[@r5] suggested that T~3~-T~4~ patients should receive PMRT. Rangan *et al*.[@r22] reported that LRR rate of patients with one to three positive lymph nodes who received chemotherapy and endocrine therapy is approximately 10% under the condition of non-PMRT. To further determine whether PMRT is essential for patients receiving endocrine therapy and whether ER/PR (--) patients could benefit from it, we analyzed its effects on LRFFS and OS of T~3~-T~4~ N~1~ patients with ER/PR (--) and who received endocrine therapy, respectively. The results of stratification analysis indicated that PMRT caused a statistically significant improvement in LRFFS and OS of T~3~-T~4~ N~1~ patients with ER/PR (--). For T~3~-T~4~ N~1~ patients who received endocrine therapy, PMRT could improve local control but no statistical change in OS was observed compared with non-PMRT.

PMRT alleviates local symptoms but often results in significant pathological damage to the heart, lungs, and skin. A meta-analysis by Taghian *et al*.[@r19] revealed a significant increase in non-breast cancer mortality in irradiated women. The mortality is mainly because of heart disease and lung cancer. Given the complications of PMRT, its necessity for T~3~-T~4~ N~1~ patients receiving endocrine therapy should be reconsidered because no statistical effect on OS was observed in this study despite the improvement in local control.

Conclusion
==========

According to our results, PMRT is highly recommended to improve LRFFS and OS for T~1~-T~2~ N~1~ patients with ECE (+) or pathological grade III as well as for T~3~-T~4~ N~1~ patients with ER/PR (--). However, PMRT has to be reconsidered for T~3~-T~4~ N~1~ patients with ER/PR (+) who benefited from endocrine therapy on improving LRFFS and OS. Other prognostic factors should be considered, and the decision has to be made individually on the basis of endocrine therapy and request of the patient because PMRT could control LRR but not total mortality.
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